About

About Xentria, Inc. Our name Xentria, derived from "centrality," reflects our commitment to pioneering solutions in drug development. Our clinical-stage biotech collaborates with biopharmaceutical communities to tackle tough challenges in healthcare. Xentria is dedicated to advancing early-stage assets through clinical development, bringing them closer to commercialization. Xentria's flagship asset, XTMAB-16, is an anti-TNFa mAb undergoing a Phase 2 trial for pulmonary sarcoidosis, a rare inflammatory disorder. Positioned as one of the few therapeutics developed specifically for this condition, XTMAB-16 signifies our dedication to addressing unmet needs. Xentria prioritizes collaboration and are open to partnering with commercial entities to provide accessible treatments for patients.